Prosecution Insights
Last updated: April 19, 2026

Fundamental Pharma GmbH

2 pending office actions

Portfolio Summary

2
Total Pending OAs
1
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18041226 NOVEL MEANS TO PREDICT AND MANIPULATE NMDA RECEPTOR-MEDIATED TOXICITY GURLEY, JAMI MICHELLE 1647 Non-Final OA Feb 10, 2023
17286207 NOVEL MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY DABKOWSKI, ERINNE R 1654 Final Rejection Apr 16, 2021

Managing Fundamental Pharma GmbH's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month